UCB Highlights Long-Term Efficacy Data for gMG Treatments at AANEM and MGFA
Event summary
- UCB presented 120-week post hoc analysis data for zilucoplan and Phase 3 study data for rozanolixizumab at the 2026 AANEM Annual Meeting and MGFA Scientific Session.
- New research underscores the burden of ocular MG and the limitations of traditional socioeconomic status indicators in identifying risks for Black gMG patients.
- Interim Phase 1b data for cizutamig, a BCMA×CD3 T-cell engager acquired through Candid Therapeutics, was also presented.
The big picture
UCB's presentation of long-term efficacy data for its gMG treatments underscores its leadership in targeted therapies. The focus on patient outcomes and health disparities aligns with broader industry trends toward personalized medicine and inclusive healthcare. With the acquisition of Candid Therapeutics, UCB is also strengthening its pipeline in immunology.
What we're watching
- Clinical Efficacy
- How long-term data for zilucoplan and rozanolixizumab will impact UCB's market positioning in gMG treatments.
- Patient-Centered Care
- Whether UCB's focus on patient perspectives will drive regulatory and reimbursement advantages.
- Pipeline Development
- The pace at which cizutamig advances through clinical trials following promising interim Phase 1b results.